130 related articles for article (PubMed ID: 9434462)
41. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
42. Structure determination of metabolites isolated from urine and bile after administration of AY4166, a novel D-phenylalanine-derivative hypoglycemic agent.
Takesada H; Matsuda K; Ohtake R; Mihara R; Ono I; Tanaka K; Naito M; Yatagai M; Suzuki E
Bioorg Med Chem; 1996 Oct; 4(10):1771-81. PubMed ID: 8931947
[TBL] [Abstract][Full Text] [Related]
43. Inhibitory effect of novel oral hypoglycemic agent nateglinide (AY4166) on peptide transporters PEPT1 and PEPT2.
Terada T; Sawada K; Saito H; Hashimoto Y; Inui K
Eur J Pharmacol; 2000 Mar; 392(1-2):11-7. PubMed ID: 10748266
[TBL] [Abstract][Full Text] [Related]
44. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
Shimabukuro M; Higa N; Takasu N; Tagawa T; Ueda S
Diabet Med; 2004 Sep; 21(9):983-6. PubMed ID: 15317602
[TBL] [Abstract][Full Text] [Related]
45. Pharmacodynamics, insulinotropic action and hypoglycemic effect of nateglinide and glibenclamide in normal and diabetic rats.
Courtois P; Jijakli H; Ladriere L; Oguzhan B; Sener A; Malaisse WJ
Int J Mol Med; 2003 Jan; 11(1):105-9. PubMed ID: 12469228
[TBL] [Abstract][Full Text] [Related]
46. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation.
McKillop AM; Duffy NA; Lindsay JR; Green BD; Patterson S; O'Harte FP; Bell PM; Flatt PR
Eur J Endocrinol; 2009 Dec; 161(6):877-85. PubMed ID: 19755410
[TBL] [Abstract][Full Text] [Related]
47. Effects of nateglinide and repaglinide administered intracerebroventricularly on the CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice.
Kim CH; Park SH; Sim YB; Kim SS; Kim SJ; Lim SM; Jung JS; Suh HW
Brain Res Bull; 2014 May; 104():36-41. PubMed ID: 24704461
[TBL] [Abstract][Full Text] [Related]
48. [Structures and mechanisms for non SU insulin secretagogues].
Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
[No Abstract] [Full Text] [Related]
49. Ay-4166 increases the sensitivity of insulin secretion to glucose in isolated perfused rat pancreas.
Morimoto S; Mokuda O; Sakamoto Y
Horm Metab Res; 1998 Feb; 30(2):77-9. PubMed ID: 9543688
[TBL] [Abstract][Full Text] [Related]
50. Role of early insulin secretion in postglucose-loading hyperglycaemia and postfat-loading hyperlipidaemia: comparing nateglinide and glibenclamide for acute effects on insulin secretion in OLETF rats.
Mori Y; Kitahara Y; Miura K; Mine T; Tajima N
Diabetes Obes Metab; 2004 Nov; 6(6):422-31. PubMed ID: 15479218
[TBL] [Abstract][Full Text] [Related]
51. Type 2 diabetes management.
Nelson G
Br J Community Nurs; 2002 Jan; 7(1):5. PubMed ID: 11823724
[No Abstract] [Full Text] [Related]
52. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
[TBL] [Abstract][Full Text] [Related]
53. [Evaluation of first phase insulin secretion by a nateglinide-intravenous glucose insulin release test in newly diagnosed type 2 diabetics].
Luo GC; Liang Z; Hu QH; Chai J; Li MZ; Yan DW; Li HY
Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):646-9. PubMed ID: 17074149
[TBL] [Abstract][Full Text] [Related]
54. The mechanisms underlying the unique pharmacodynamics of nateglinide.
Hu S; Boettcher BR; Dunning BE
Diabetologia; 2003 Mar; 46 Suppl 1():M37-43. PubMed ID: 12652357
[TBL] [Abstract][Full Text] [Related]
55. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
[TBL] [Abstract][Full Text] [Related]
56. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
57. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
[TBL] [Abstract][Full Text] [Related]
58. [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
Hirose T
Nihon Rinsho; 2005 Dec; 63(12):2237-44. PubMed ID: 16363700
[TBL] [Abstract][Full Text] [Related]
59. Nateglinide controlled release tablet containing compressionable enteric coated granules.
Makino C; Sakai H; Yabuki A
Chem Pharm Bull (Tokyo); 2010 Sep; 58(9):1136-41. PubMed ID: 20823590
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the rapidity of onset of the therapeutic effect between nateglinide and mitiglinide by PK/PD analysis in rats.
Takanohashi T; Arisaka H; Ubukata K; Hayashi M; Yamada Y
Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):9-15. PubMed ID: 22012638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
